Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 15 Feb 2019
At a glance
- Drugs Onasemnogene-abeparvovec (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- Acronyms REACH
- Sponsors AveXis
- 08 Feb 2019 Status changed from planning to not yet recruiting.
- 18 Jan 2018 New trial record
- 16 Jan 2018 According to a AveXis media release, this trial may expect to start in late Q4 2018 or early 2019.